Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085697 | 0.97 | CSNK1D (0.51) | CSNK1DADORA2AHRH3KDM4ETSHR | |
| SCHEMBL4080007 | 0.89 | CSNK1D (0.49) | CSNK1DADORA2AHRH3LRRK2ABL1 | |
| SCHEMBL4080009 | 0.89 | CSNK1D (0.49) | CSNK1DADORA2AHRH3LRRK2ABL1 | |
| SCHEMBL5246773 | 0.87 | CSNK1D (0.68) | CSNK1DADORA2AHRH3KDM4ELRRK2 | |
| SCHEMBL4090371 | 0.86 | CSNK1D (0.67) | CSNK1DADORA2AHRH3KDM4ELRRK2 | |
| SCHEMBL13812173 | 0.86 | CSNK1D (0.56) | CSNK1DHRH3 | |
| SCHEMBL4083423 | 0.85 | CSNK1D (0.66) | CSNK1DADORA2AHRH3KDM4ELRRK2 | |
| SCHEMBL4084738 | 0.85 | CSNK1D (0.65) | CSNK1DADORA2AHRH3KDM4ELRRK2 | |
| SCHEMBL13811889 | 0.84 | HRH3 (0.43) | CSNK1DHRH3KDM4ETSHRLRRK2 | |
| SCHEMBL13812276 | 0.84 | CSNK1D (0.45) | CSNK1DHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | CSNK1D 702/4885ADORA2A 1535/4885HRH3 2504/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | CSNK1D 687/4885ADORA2A 1577/4885HRH3 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.